This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Sanofi is to buy the vaccines biotech Protein Sciences in a deal worth up to $750 million, after missing out on bigger acquisitions. The French drugmaker tried to buy cancer drugs firm Medivation ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

Before the Sanofi acquisition closes, Inhibrx will spin off its other drug assets, which target various cancers, into a company to be called New Inhibrx. That firm will have $200 million in cash ...

Crossmark Global Holdings Inc. increased its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 23.7% during the ...

He added that while there was no timeline for how long Sanofi would be involved in Opella, "we expect to be involved and in partnership for a long time". Opella employs 11,000 people globally and ...

The acquisition of INBRX-101 is seen as a step towards strengthening Sanofi’s rare disease business. Following the acquisition, New Inhibrx will continue to operate under the “Inhibrx” name ...